TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...
Multiple Sclerosis News Today6d
Ocrevus Zunovo now approved in US to treat relapsing MS, PPMS
The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...
GlobalData on MSN6d
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech
Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...
Pharmabiz5d
US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS
US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS: Basel Tuesday, September 17, 2024, 10:00 Hrs [IST] Roche announced that the United States ...
Managed Healthcare Executive6d
FDA Approves Subcutaneous Ocrevus for Multiple Sclerosis
Ocrevus Zunovo can be administrated by providers twice a year with a 10-minute subcutaneous injection. Ocrevus Zunovo will be ...
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...
Yahoo Finance6d
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech
which demonstrated non-inferior levels of Ocrevus in the bloodstream when administered subcutaneously compared to the intravenous formulation. The trial also confirmed a comparable safety and ...
pharmaphorum5d
Roche preps filings for new Ocrevus injection
A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according to the company ...